Trelegy Ellipta is for adult patients with moderate/severe COPD on treatment with an ICS/LABA or LAMA/LABA who are symptomatic and at risk of an exacerbation14

ERS 2022 Symposium Summary with Professor Meilan Han & Dr Chris Compton

How molecular pharmacology is improving patient outcomes in COPD

Trelegy consists of an ICS, a LABA, and a LAMA. delivered in the Ellipta inhaler14

Ellipta open inhaler close
  • Slide the cover down until you hear a ‘click’.
  • While holding the inhaler away from your mouth, breathe out as far as comfortable
Ellipta open inhaler close
  • Put the mouthpiece between your lips, and close your lips firmly around it.
  • Take one long, steady, deep breath in and hold this breath for at least 3-4 seconds
Ellipta open inhaler close
  • Remove the inhaler from your mouth and breathe out slowly and gently.
  • Slide the cover upwards as far as it will go to cover the mouthpiece.

Get started with Trelegy Ellipta

Prescribing Information Links

Trelegy Ellipta Prescribing Information (pdf)
Relvar Ellipta Prescribing Information (pdf)
Anoro Ellipta Prescribing Information (pdf)
Incruse Ellipta Prescribing Information (pdf)

Trelegy Ellipta OD is indicated for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting β2-agonist or a combination of a long-acting β2-agonist and a long-acting muscarinic antagonist.14

Abbreviations

DPI, dry powder inhaler; FEV1, forced expiratory volume in one second; FF, fluticasone furoate; FOR, formoterol; HRQoL, health-related quality of life; ICS, inhaled corticosteroid; ITT, intent-to-treat; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; OD, once daily; QoL, quality of life; pMDI, pressurised metered dose inhaler; UMEC, umeclidinium; VI, vilanterol

References

  1. IQVIA MIDAS data, volume (units) since launch up to (and including) November 2021
  2. GSK 50 years of innovation REF-36689
  3. Vestbo J et al N Engl J Med 2016; 375:1253-60
  4. Maltais F et al Adv Ther 2019; 36:2434-2449
  5. Feldman G Adv Ther 2017 34:2518-2533
  6. Feldman GJ et al Int J Chron Obstruct Pulmon Dis 2016: 11:719-730
  7. Certification of carbon neutrality for Trelegy Ellipta
  8. van der Palen J. et al NPJ P rim Care Respir Med 2016 26:16079
  9. IQVIA DRx Patient on treatment, Aug 2022
  10. Department of health - An Outcomes Strategy for Chronic Obstructive Pulmonary Disease (COPD) and Asthma in England
  11. LPD, IQVIA Ltd, incorporating data derived from THIN, A Cegedim Database, Aug 2022
  12. British Thoracic Society (BTS) 2020 Position Statement: Environment and Lung Health
  13. The NHS Long Term Plan 2019
  14. Trelegy Ellipta SmPC

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

February 2023 | PM-GB-FVU-WCNT-200014 (V7.0)